{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T12:49:40Z","timestamp":1774788580931,"version":"3.50.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T00:00:00Z","timestamp":1355875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inflammation"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s10753-012-9585-8","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T10:20:53Z","timestamp":1355826053000},"page":"633-642","source":"Crossref","is-referenced-by-count":30,"title":["Is the CCR5 \u0394 32 Mutation Associated with Immune System-Related Diseases?"],"prefix":"10.1007","volume":"36","author":[{"given":"Khodayar","family":"Ghorban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Dadmanesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholamhossein","family":"Hassanshahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Momeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Zare-Bidaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Kazemi","family":"Arababadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,19]]},"reference":[{"key":"9585_CR1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/35003235","volume":"403","author":"YJ Chiang","year":"2000","unstructured":"Chiang, Y.J., H.K. Kole, K. Brown, et al. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403: 216\u2013220.","journal-title":"Nature"},{"key":"9585_CR2","doi-asserted-by":"crossref","unstructured":"Arababadi M. K., Ahmadabadi B. N., Kennedy D. 2012. Current information on the immunological status of occult hepatitis B infection. Transfusion 52: 1819\u20131826.","DOI":"10.1111\/j.1537-2995.2012.03575.x"},{"key":"9585_CR3","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0264-410X(02)00538-8","volume":"21","author":"W Eden van","year":"2003","unstructured":"van Eden, W., A. Koets, P. van Kooten, et al. 2003. Immunopotentiating heat shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine 21: 897\u2013901.","journal-title":"Vaccine"},{"key":"9585_CR4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaci.2009.03.001","volume":"123","author":"M Miyara","year":"2009","unstructured":"Miyara, M., K. Wing, and S. Sakaguchi. 2009. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. J Allergy Clin Immunol 123: 749\u2013755. quiz 756\u2013747.","journal-title":"J Allergy Clin Immunol"},{"key":"9585_CR5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/0256-4947.60516","volume":"30","author":"SA Al-Abdulhadi","year":"2010","unstructured":"Al-Abdulhadi, S.A., and M.W. Al-Rabia. 2010. Linkage and haplotype analysis for chemokine receptors clustered on chromosome 3p21.3 and transmitted in family pedigrees with asthma and atopy. Ann Saudi Med 30: 115\u2013122.","journal-title":"Ann Saudi Med"},{"key":"9585_CR6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1471-4906(02)02252-4","volume":"23","author":"T Lehner","year":"2002","unstructured":"Lehner, T. 2002. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol 23: 347\u2013351.","journal-title":"Trends Immunol"},{"key":"9585_CR7","doi-asserted-by":"crossref","unstructured":"Ahmadabadi, B.N., G. Hassanshahi, H. Khoramdelazad, et al. 2012. Down-regulation of CCR5 expression on the peripheral blood CD8+ T cells of South-Eastern Iranian patients with chronic hepatitis B infection. Inflammation. doi: 10.1007\/s10753-012-9528-4 .","DOI":"10.1007\/s10753-012-9528-4"},{"key":"9585_CR8","doi-asserted-by":"crossref","first-page":"e33747","DOI":"10.1371\/journal.pone.0033747","volume":"7","author":"JK Song","year":"2012","unstructured":"Song, J.K., M.H. Park, D.Y. Choi, et al. 2012. Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kappaB and upregulation of IL-1Ra in melanoma model. PLoS One 7: e33747.","journal-title":"PLoS One"},{"key":"9585_CR9","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2008-01-135111","volume":"112","author":"HF Kuipers","year":"2008","unstructured":"Kuipers, H.F., P.J. Biesta, L.J. Montagne, et al. 2008. CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor. Blood 112: 1610\u20131619.","journal-title":"Blood"},{"key":"9585_CR10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/10606820212135","volume":"8","author":"C Blanpain","year":"2002","unstructured":"Blanpain, C., F. Libert, G. Vassart, et al. 2002. CCR5 and HIV infection. Receptors Channels 8: 19\u201331.","journal-title":"Receptors Channels"},{"key":"9585_CR11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pneurobio.2010.12.003","volume":"93","author":"S Sorce","year":"2011","unstructured":"Sorce, S., R. Myburgh, and K.H. Krause. 2011. The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol 93: 297\u2013311.","journal-title":"Prog Neurobiol"},{"key":"9585_CR12","doi-asserted-by":"crossref","first-page":"11427","DOI":"10.1074\/jbc.M010750200","volume":"276","author":"M Wong","year":"2001","unstructured":"Wong, M., S. Uddin, B. Majchrzak, et al. 2001. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem 276: 11427\u201311431.","journal-title":"J Biol Chem"},{"key":"9585_CR13","first-page":"735","volume":"41","author":"MK Arababadi","year":"2010","unstructured":"Arababadi, M.K., A.A. Pourfathollah, A. Jafarzadeh, et al. 2010. Decreased expression of CCR5 on the NK cells in occult HBV infected patients. LabMedicine 41: 735\u2013738.","journal-title":"LabMedicine"},{"key":"9585_CR14","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1128\/JVI.01596-07","volume":"82","author":"Q Jin","year":"2008","unstructured":"Jin, Q., L. Agrawal, L. Meyer, et al. 2008. CCR5Delta32 59537-G\/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects. J Virol 82: 2418\u20132426.","journal-title":"J Virol"},{"key":"9585_CR15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3727\/096504008784523667","volume":"17","author":"H Singh","year":"2008","unstructured":"Singh, H., R. Sachan, M. Jain, et al. 2008. CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol Res 17: 87\u201391.","journal-title":"Oncol Res"},{"key":"9585_CR16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3748\/wjg.14.713","volume":"14","author":"P Nahon","year":"2008","unstructured":"Nahon, P., A. Sutton, P. Rufat, et al. 2008. Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 14: 713\u2013719.","journal-title":"World J Gastroenterol"},{"key":"9585_CR17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.biopha.2007.04.005","volume":"62","author":"FR Guerini","year":"2008","unstructured":"Guerini, F.R., S. Delbue, M. Zanzottera, et al. 2008. Analysis of CCR5, CCR2, SDF1 and RANTES gene polymorphisms in subjects with HIV-related PML and not determined leukoencephalopathy. Biomed Pharmacother 62: 26\u201330.","journal-title":"Biomed Pharmacother"},{"key":"9585_CR18","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/SMJ.0b013e3182186ff0","volume":"104","author":"H Abousaidi","year":"2011","unstructured":"Abousaidi, H., R. Vazirinejad, M.K. Arababadi, et al. 2011. Lack of association between chemokine receptor 5 (CCR5) delta32 mutation and pathogenesis of asthma in Iranian patients. South Med J 104: 422\u2013425.","journal-title":"South Med J"},{"key":"9585_CR19","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1201431","volume":"189","author":"MW Richardson","year":"2012","unstructured":"Richardson, M.W., J. Jadlowsky, C.A. Didigu, et al. 2012. Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. J Immunol 189: 3815\u20133821.","journal-title":"J Immunol"},{"key":"9585_CR20","doi-asserted-by":"crossref","first-page":"e35020","DOI":"10.1371\/journal.pone.0035020","volume":"7","author":"S Liu","year":"2012","unstructured":"Liu, S., C. Kong, J. Wu, et al. 2012. Effect of CCR5-Delta32 heterozygosity on HIV-1 susceptibility: a meta-analysis. PLoS One 7: e35020.","journal-title":"PLoS One"},{"key":"9585_CR21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.diabres.2009.08.013","volume":"86","author":"FL Muntinghe","year":"2009","unstructured":"Muntinghe, F.L., S. Gross, S.J. Bakker, et al. 2009. CCR5Delta32 genotype is associated with outcome in type 2 diabetes mellitus. Diabetes Res Clin Pract 86: 140\u2013145.","journal-title":"Diabetes Res Clin Pract"},{"key":"9585_CR22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0165-5728(99)00166-6","volume":"102","author":"F Sellebjerg","year":"2000","unstructured":"Sellebjerg, F., H.O. Madsen, C.V. Jensen, et al. 2000. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 102: 98\u2013106.","journal-title":"J Neuroimmunol"},{"key":"9585_CR23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.mcp.0000144502.50149.e0","volume":"11","author":"LR Bisset","year":"2005","unstructured":"Bisset, L.R., and P. Schmid-Grendelmeier. 2005. Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective. Curr Opin Pulm Med 11: 35\u201342.","journal-title":"Curr Opin Pulm Med"},{"key":"9585_CR24","doi-asserted-by":"crossref","first-page":"B5","DOI":"10.1038\/35037002","volume":"402","author":"W Cookson","year":"1999","unstructured":"Cookson, W. 1999. The alliance of genes and environment in asthma and allergy. Nature 402: B5\u201311.","journal-title":"Nature"},{"key":"9585_CR25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/ers.10.57","volume":"4","author":"K Orihara","year":"2011","unstructured":"Orihara, K., N. Dil, V. Anaparti, et al. 2011. What's new in asthma pathophysiology and immunopathology? Expert Rev Respir Med 4: 605\u2013629.","journal-title":"Expert Rev Respir Med"},{"key":"9585_CR26","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","volume":"476","author":"S Sawcer","year":"2011","unstructured":"Sawcer, S., G. Hellenthal, M. Pirinen, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214\u2013219.","journal-title":"Nature"},{"key":"9585_CR27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2217\/bmm.10.81","volume":"4","author":"MK Arababadi","year":"2010","unstructured":"Arababadi, M.K., R. Mosavi, H. Khorramdelazad, et al. 2010. Cytokine patterns after therapy with Avonex(R), Rebif(R), Betaferon(R) and CinnoVex in relapsing-remitting multiple sclerosis in Iranian patients. Biomark Med 4: 755\u2013759.","journal-title":"Biomark Med"},{"key":"9585_CR28","doi-asserted-by":"crossref","unstructured":"Arababadi M. K., Mosavi R., Teimori H., et al. 2011. Association of IL-4 polymorphisms with multiple sclerosis in south-eastern Iranian patients. Ann Saudi Med 32: 127\u2013130.","DOI":"10.5144\/0256-4947.2012.127"},{"key":"9585_CR29","doi-asserted-by":"crossref","unstructured":"Yaghini N., Mahmoodi M., Asadikaram G., et al. 2012. Genetic variation of IL-12B (+1188 region) is associated with its decreased circulating levels and susceptibility to type 2 diabetes: a study on south-eastern Iranian diabetic patients. Biomark Med 6: 89\u201395.","DOI":"10.2217\/bmm.11.84"},{"key":"9585_CR30","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/BF03346417","volume":"31","author":"M Cruz","year":"2008","unstructured":"Cruz, M., C. Maldonado-Bernal, R. Mondragon-Gonzalez, et al. 2008. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. J Endocrinol Invest 31: 694\u2013699.","journal-title":"J Endocrinol Invest"},{"key":"9585_CR31","doi-asserted-by":"crossref","unstructured":"Yaghini N., Mahmoodi M., Asadikaram G., et al. 2011. Serum levels of Interleukin 10 (IL-10) in patients with type 2 diabetes. Iran Red Cres Med J 13: 752.","DOI":"10.1016\/j.clinbiochem.2011.08.355"},{"key":"9585_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.diabres.2009.09.027","volume":"87","author":"MK Arababadi","year":"2009","unstructured":"Arababadi, M.K., R. Nosratabadi, G. Hassanshahi, et al. 2009. Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases? Diabetes Res Clin Pract 87: 33\u201337.","journal-title":"Diabetes Res Clin Pract"},{"key":"9585_CR33","first-page":"302","volume":"4","author":"MK Arababadi","year":"2010","unstructured":"Arababadi, M.K. 2010. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iran J Kidney Dis 4: 302\u2013306.","journal-title":"Iran J Kidney Dis"},{"key":"9585_CR34","first-page":"100","volume":"12","author":"MK Arababadi","year":"2009","unstructured":"Arababadi, M.K., A.A. Pourfathollah, S. Daneshmandi, et al. 2009. Evaluation of relation between IL-4 and IFN-g polymorphisms and type 2 diabetes. Iran J Bas Med Sci 12: 100\u2013104.","journal-title":"Iran J Bas Med Sci"},{"key":"9585_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1744-313X.2010.00953.x","volume":"37","author":"R Nosratabadi","year":"2010","unstructured":"Nosratabadi, R., M.K. Arababadi, V.A. Salehabad, et al. 2010. Polymorphisms within exon 9 but not intron 8 of the vitamin D receptor are associated with the nephropathic complication of type-2 diabetes. Int J Immunogenet 37: 1\u20135.","journal-title":"Int J Immunogenet"},{"key":"9585_CR36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4103\/0256-4947.55177","volume":"29","author":"MK Arababadi","year":"2009","unstructured":"Arababadi, M.K., N. Naghavi, G. Hassanshahi, et al. 2009. Is CCR5-Delta32 mutation associated with diabetic nephropathy in type 2 diabetes? Ann Saudi Med 29: 413.","journal-title":"Ann Saudi Med"},{"key":"9585_CR37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.cyto.2011.08.017","volume":"56","author":"M Neumeier","year":"2011","unstructured":"Neumeier, M., S. Bauer, H. Bruhl, et al. 2011. Adiponectin stimulates release of CCL2, -3, -4 and -5 while the surface abundance of CCR2 and -5 is simultaneously reduced in primary human monocytes. Cytokine 56: 573\u2013580.","journal-title":"Cytokine"},{"key":"9585_CR38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1902\/jop.2009.090358","volume":"81","author":"I Venza","year":"2010","unstructured":"Venza, I., M. Visalli, M. Cucinotta, et al. 2010. Proinflammatory gene expression at chronic periodontitis and peri-implantitis sites in patients with or without type 2 diabetes. J Periodontol 81: 99\u2013108.","journal-title":"J Periodontol"},{"key":"9585_CR39","doi-asserted-by":"crossref","first-page":"563","DOI":"10.5414\/CPP45563","volume":"45","author":"P Bogdanski","year":"2007","unstructured":"Bogdanski, P., D. Pupek-Musialik, J. Dytfeld, et al. 2007. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. Int J Clin Pharmacol Ther 45: 563\u2013567.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"9585_CR40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1056-8727(02)00242-8","volume":"17","author":"I Kalev","year":"2003","unstructured":"Kalev, I., K. Oselin, P. Parlist, et al. 2003. CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. J Diabetes Complications 17: 387\u2013391.","journal-title":"J Diabetes Complications"},{"key":"9585_CR41","doi-asserted-by":"crossref","first-page":"e5168","DOI":"10.1371\/journal.pone.0005168","volume":"4","author":"TS Ahluwalia","year":"2009","unstructured":"Ahluwalia, T.S., M. Khullar, M. Ahuja, et al. 2009. Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 4: e5168.","journal-title":"PLoS One"},{"key":"9585_CR42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1474-4422(10)70086-7","volume":"9","author":"A Ascherio","year":"2010","unstructured":"Ascherio, A., K.L. Munger, and K.C. Simon. 2010. Vitamin D and multiple sclerosis. Lancet Neurol 9: 599\u2013612.","journal-title":"Lancet Neurol"},{"key":"9585_CR43","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2217\/17520363.1.1.111","volume":"1","author":"CE Teunissen","year":"2007","unstructured":"Teunissen, C.E., J. Killestein, and G. Giovannoni. 2007. Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. Biomark Med 1: 111\u2013119.","journal-title":"Biomark Med"},{"key":"9585_CR44","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","volume":"140","author":"CK Glass","year":"2010","unstructured":"Glass, C.K., K. Saijo, B. Winner, et al. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918\u2013934.","journal-title":"Cell"},{"key":"9585_CR45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2009.10.015","volume":"221","author":"R Gandhi","year":"2010","unstructured":"Gandhi, R., A. Laroni, and H.L. Weiner. 2010. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol 221: 7\u201314.","journal-title":"J Neuroimmunol"},{"key":"9585_CR46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1600-0404.2006.00749.x","volume":"115","author":"A Szczucinski","year":"2007","unstructured":"Szczucinski, A., and J. Losy. 2007. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol Scand 115: 137\u2013146.","journal-title":"Acta Neurol Scand"},{"key":"9585_CR47","first-page":"31","volume":"41","author":"MK Arababadi","year":"2010","unstructured":"Arababadi, M.K., G. Hassanshahi, H. Azin, et al. 2010. No association between CCR5-\u0394 32 mutation and multiple sclerosis in patients of south-eastern of Iran. LabMedicine 41: 31\u201333.","journal-title":"LabMedicine"},{"key":"9585_CR48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0198-8859(97)00207-3","volume":"58","author":"BH Bennetts","year":"1997","unstructured":"Bennetts, B.H., S.M. Teutsch, M.M. Buhler, et al. 1997. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 58: 52\u201359.","journal-title":"Hum Immunol"},{"key":"9585_CR49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jneuroim.2005.07.025","volume":"169","author":"OH Kantarci","year":"2005","unstructured":"Kantarci, O.H., Y. Morales, P.A. Ziemer, et al. 2005. CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol 169: 137\u2013143.","journal-title":"J Neuroimmunol"},{"key":"9585_CR50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1191\/1352458504ms994oa","volume":"10","author":"JA Silversides","year":"2004","unstructured":"Silversides, J.A., S.V. Heggarty, G.V. McDonnell, et al. 2004. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. Mult Scler 10: 149\u2013152.","journal-title":"Mult Scler"},{"key":"9585_CR51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0304-3940(02)00807-8","volume":"330","author":"CG Haase","year":"2002","unstructured":"Haase, C.G., S. Schmidt, and P.M. Faustmann. 2002. Frequencies of the G-protein beta3 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci Lett 330: 293\u2013295.","journal-title":"Neurosci Lett"},{"key":"9585_CR52","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1600-0404.2007.00826.x","volume":"115","author":"F Sellebjerg","year":"2007","unstructured":"Sellebjerg, F., T.B. Kristiansen, P. Wittenhagen, et al. 2007. Chemokine receptor CCR5 in interferon-treated multiple sclerosis. Acta Neurol Scand 115: 413\u2013418.","journal-title":"Acta Neurol Scand"},{"key":"9585_CR53","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0165-5728(02)00037-1","volume":"125","author":"F Sellebjerg","year":"2002","unstructured":"Sellebjerg, F., G. Giovannoni, A. Hand, et al. 2002. Cerebrospinal fluid levels of nitric oxide metabolites predict response to methylprednisolone treatment in multiple sclerosis and optic neuritis. J Neuroimmunol 125: 198\u2013203.","journal-title":"J Neuroimmunol"},{"key":"9585_CR54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10571-009-9415-1","volume":"29","author":"M Shahbazi","year":"2009","unstructured":"Shahbazi, M., H. Ebadi, D. Fathi, et al. 2009. CCR5-delta32 allele is associated with the risk of developing multiple sclerosis in the Iranian population. Cell Mol Neurobiol 29: 29.","journal-title":"Cell Mol Neurobiol"},{"key":"9585_CR55","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/01.GIM.0000127274.45301.54","volume":"6","author":"R Gade-Andavolu","year":"2004","unstructured":"Gade-Andavolu, R., D.E. Comings, J. MacMurray, et al. 2004. Association of CCR5 delta32 deletion with early death in multiple sclerosis. Genet Med 6: 126\u2013131.","journal-title":"Genet Med"},{"key":"9585_CR56","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000035626.92372.0A","volume":"59","author":"OO Favorova","year":"2002","unstructured":"Favorova, O.O., T.V. Andreewski, A.N. Boiko, et al. 2002. The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians. Neurology 59: 1652\u20131655.","journal-title":"Neurology"},{"key":"9585_CR57","first-page":"153282","volume":"2011","author":"R D'Angelo","year":"2011","unstructured":"D'Angelo, R., C. Crisafulli, C. Rinaldi, et al. 2011. CCR5Delta32 polymorphism associated with a slower rate disease progression in a cohort of RR-MS Sicilian patients. Mult Scler Int 2011: 153282.","journal-title":"Mult Scler Int"},{"key":"9585_CR58","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1046\/j.1600-0404.2003.00233.x","volume":"109","author":"K Pulkkinen","year":"2004","unstructured":"Pulkkinen, K., M. Luomala, H. Kuusisto, et al. 2004. Increase in CCR5 Delta32\/Delta32 genotype in multiple sclerosis. Acta Neurol Scand 109: 342\u2013347.","journal-title":"Acta Neurol Scand"},{"key":"9585_CR59","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1067\/mai.2001.116122","volume":"108","author":"AJ Sandford","year":"2001","unstructured":"Sandford, A.J., S. Zhu, T.R. Bai, et al. 2001. The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. J Allergy Clin Immunol 108: 69\u201373.","journal-title":"J Allergy Clin Immunol"},{"key":"9585_CR60","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.rmed.2008.03.010","volume":"102","author":"Z Zietkowski","year":"2008","unstructured":"Zietkowski, Z., M.M. Tomasiak, R. Skiepko, et al. 2008. RANTES in exhaled breath condensate of stable and unstable asthma patients. Respir Med 102: 1198\u20131202.","journal-title":"Respir Med"},{"key":"9585_CR61","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1146\/annurev.immunol.19.1.683","volume":"19","author":"KW Moore","year":"2001","unstructured":"Moore, K.W., R. de Waal Malefyt, R.L. Coffman, et al. 2001. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683\u2013765.","journal-title":"Annu Rev Immunol"},{"key":"9585_CR62","doi-asserted-by":"crossref","unstructured":"Abousaidi H., Vazirinejad R., Arababadi M. K., et al. 2011. Lack of association between chemokine receptor 5 (CCR5) C32 mutation and pathogenesis of Asthma: A Study on Iranian Asthma Patients. South Med J 104: 422\u2013425.","DOI":"10.1097\/SMJ.0b013e3182186ff0"},{"key":"9585_CR63","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)03144-5","volume":"356","author":"TJ Mitchell","year":"2000","unstructured":"Mitchell, T.J., A.J. Walley, J.E. Pease, et al. 2000. Delta 32 deletion of CCR5 gene and association with asthma or atopy. Lancet 356: 1491\u20131492.","journal-title":"Lancet"},{"key":"9585_CR64","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0140-6736(05)72005-5","volume":"355","author":"C Szalai","year":"2000","unstructured":"Szalai, C., A. Bojszko, G. Beko, et al. 2000. Prevalence of CCR5delta32 in allergic diseases. Lancet 355: 66.","journal-title":"Lancet"},{"key":"9585_CR65","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/adc.86.6.426","volume":"86","author":"A Nagy","year":"2002","unstructured":"Nagy, A., G.T. Kozma, A. Bojszko, et al. 2002. No association between asthma or allergy and the CCR5Delta 32 mutation. Arch Dis Child 86: 426.","journal-title":"Arch Dis Child"},{"key":"9585_CR66","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2370.2002.00357.x","volume":"29","author":"R McGinnis","year":"2002","unstructured":"McGinnis, R., F. Child, S. Clayton, et al. 2002. Further support for the association of CCR5 allelic variants with asthma susceptibility. Eur J Immunogenet 29: 525\u2013528.","journal-title":"Eur J Immunogenet"},{"key":"9585_CR67","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/thorax.58.3.222","volume":"58","author":"P Srivastava","year":"2003","unstructured":"Srivastava, P., P.J. Helms, D. Stewart, et al. 2003. Association of CCR5Delta32 with reduced risk of childhood but not adult asthma. Thorax 58: 222\u2013226.","journal-title":"Thorax"},{"key":"9585_CR68","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/S0140-6736(99)03425-X","volume":"354","author":"IP Hall","year":"1999","unstructured":"Hall, I.P., A. Wheatley, G. Christie, et al. 1999. Association of CCR5 delta32 with reduced risk of asthma. Lancet 354: 1264\u20131265.","journal-title":"Lancet"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-012-9585-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10753-012-9585-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-012-9585-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T04:48:55Z","timestamp":1562474935000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10753-012-9585-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,19]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["9585"],"URL":"https:\/\/doi.org\/10.1007\/s10753-012-9585-8","relation":{},"ISSN":["0360-3997","1573-2576"],"issn-type":[{"value":"0360-3997","type":"print"},{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,19]]}}}